BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

FREE RADICAL BIOLOGY AND MEDICINE, published by Elsevier Science Inc, is a premier journal dedicated to the field of biochemistry and medical physiology. With an ISSN of 0891-5849 and an E-ISSN of 1873-4596, this journal stands out with its impressive ranking in the 2023 category quartiles: Q1 in Biochemistry and Q1 in Physiology (medical). Specifically, it has achieved a remarkable position of 29th out of 438 in Biochemistry and 8th out of 113 in Physiology, placing it firmly in the 93rd percentile of its field, as per Scopus rankings. Since its inception in 1987, the journal has focused on advancing the understanding of free radicals and their role in biological processes, encompassing a wide range of topics from oxidative stress to therapeutic applications. Although it does not currently offer open access, the journal's rigorous peer-review process and impactful research ensure that it remains a valuable resource for researchers and professionals seeking to explore the intricate relationships between free radicals and health. The journal's headquarters are located at STE 800, 230 Park Ave, New York, NY 10169, reflecting its esteemed place within the scientific community and commitment to high-quality research.

METABOLISM-CLINICAL AND EXPERIMENTAL is a premier academic journal published by W B SAUNDERS CO-ELSEVIER INC, with a distinguished history dating back to 1952. This journal serves as a vital repository of knowledge in the fields of Endocrinology, Diabetes, and Metabolism, consistently ranking in the top quartile (Q1) within these categories according to the latest metrics. With an impressive impact factor and recognized for its contributions to Biochemistry, Genetics, and Molecular Biology, it ranks #5 out of 128 in the Scopus database for Endocrinology and #11 out of 244 for Medicine related to Endocrinology, Diabetes, and Metabolism, placing it in the 95th and 96th percentiles, respectively. While the journal does not currently offer open access, it maintains rigorous peer review standards and publishes cutting-edge research that drives forward the understanding of metabolic diseases and clinical practices. By engaging with METABOLISM-CLINICAL AND EXPERIMENTAL, researchers, healthcare professionals, and students can explore groundbreaking advancements and pivotal findings that shape the future of metabolic health.

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, published by SAGE PUBLICATIONS INC, stands as a vital resource in the fields of Endocrinology and Internal Medicine. With an impressive open access model established in 2014, this journal facilitates broad dissemination of high-quality research that explores the complex mechanisms and clinical implications of the renin-angiotensin-aldosterone system (RAAS). Currently, it is recognized within the 2023 Category Quartiles as Q3 in Endocrinology and Q2 in Internal Medicine, reflecting its significant impact on the scientific community. The journal ranks in the 75th percentile for Internal Medicine and the 57th percentile in Endocrinology according to Scopus, indicating its strong contributions to these disciplines. Covering a rich history from its inception in 2000 to the present, the journal aims to bridge the gap between basic research and clinical practice, thereby enhancing the understanding and treatment of conditions influenced by RAAS. The continuous publication of innovative research makes it an essential reference for researchers, healthcare professionals, and students engaged in these dynamic fields.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.